Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinicopathological characteristics of patientsamples and expression of PTOV1 in breast cancer

From: Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer

Variables Number of cases (%)
Gender  
Male 0 (0.0)
Female 169 (100.0)
Age (years)  
≥ 47 89 (52.7)
< 47 80 (47.3)
Clinical stage  
I 30 (17.8)
II 81 (47.9)
III 53 (31.4)
IV 5 (3.0)
T classification  
T1 52 (30.8)
T2 88 (52.1)
T3 17 (10.1)
T4 12 (7.1)
N classification  
N0 72 (42.6)
N1 50 (29.6)
N2 30 (17.8)
N3 17 (10.1)
M classification  
No 164 (97)
Yes 5 (3)
Vital status (at follow-up)  
alive 131 (77.5)
Dead 38 (22.5)
Expression of PTOV1  
Low expression 86 (50.9)
High expression 83 (49.1)
Detectable 167 (99.4)
Undetectable 2 (0.6)
Expression of ER  
0 74 (43.8)
1 37 (21.9)
2 16 (9.5)
3 42 (24.9)
Expression of PR  
0 75 (44.4)
1 28 (16.6)
2 27 (16.0)
3 39 (23.1)
Expression of c-erbB2  
0 90 (53.3)
1 20 (11.8)
2 13 (7.7)
3 46 (27.2)